Compare Ferrari NV (RACE) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ferrari NV vs Stryker Corporation — how do they compare? Ferrari NV trades at $389.91 (market cap $67.35B), while Stryker Corporation trades at $277.33 (market cap $106.24B). The key difference: Stryker Corporation is the larger of the two by market cap, and Stryker Corporation pays the higher dividend (1.27%). Which is the better fit depends on your goals — on Pluang, investors hold Ferrari NV for 126 Days and Stryker Corporation for 21 Days on average.
| RACE | SYK | |
|---|---|---|
Market Cap | $67.35B | $106.24B |
Volume | 390,618 | 2,982,001 |
Sector | Consumer Cyclical | Health |
52-Week High | $436.54 | $388.35 |
52-Week Low | $314.63 | $269.75 |
Typical Hold Time | 126 Days | 21 Days |
Enterprise Value | $69.22B | $117.70B |
Dividend Yield | 1.09% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ferrari (RACE) trades at $388.28, up 0.49% today, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue grew to $7.15B in 2025, with a net income margin of 22.25% and robust ROE of 45.45%. The company is executing a share buyback program and recently announced a partnership with Rakuten effective January 2027.
The outlook is positive given strong profitability, consistent earnings beats, and analyst consensus favoring a buy rating with a $462.75 price target. Risks include high valuation multiples (P/E 37.19) and exposure to economic cycles affecting luxury demand. Institutional buying and buyback support provide downside cushion, but investors should monitor execution on future growth initiatives.
Stryker (SYK) trades at $276.97, up 0.57% today, amid a bearish technical signal with key support at $274 and resistance at $279. The company reported strong profitability with a 14.43% net income margin and beat Q2 2026 EPS estimates, though it missed in Q1. Recent news highlights ongoing legal scrutiny related to manufacturing issues disclosed in September 2026, which caused a significant share price drop.
Analyst consensus remains strongly bullish with a $368.11 price target, but risks include persistent manufacturing problems and potential securities litigation. Earnings growth and margin expansion support the long-term outlook, though near-term volatility may persist pending Q3 2026 results on October 29, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
